Browse All

Current Filters

CLEAR FILTER x

TITLE

Efficacy of Symbravo® (MoSEIC(TM) meloxicam and rizatriptan) by Baseline Migraine-associated Disability: Post-hoc Analysis of the INTERCEPT Trial 

Author:Grinnell, Todd   Tepper, Stewart   Chhabra, Angad   Eglit, Graham   Tabuteau, Herriot   

Session Name:P8: Headache: Acute, Rescue, and Short-term Prevention Migraine Pharmacologic Treatment  

Topic:Headache  

Program Number:P8.012  

Author Institution:Axsome Therapeutics, Inc., New York, NY  The New England Institute for Neurology and Headache, Stamford, CT  

Long-term Effects of Symbravo® (MoSEIC(TM) meloxicam and rizatriptan) on Headache Burden and Quality of Life: Results of the MOVEMENT Trial

Author:Grinnell, Todd   Lipton, Richard   Zhao, Yang   Chhabra, Angad   Eglit, Graham   

Session Name:P8: Headache: Acute, Rescue, and Short-term Prevention Migraine Pharmacologic Treatment  

Topic:Headache  

Program Number:P8.013  

Author Institution:Axsome Therapeutics, Inc., New York, NY  Albert Einstein College of Medicine, Bronx, NY